Other Events ·
Cardiol Therapeutics expands MAVERIC trial to up to 150 patients after early enrollment target of 110 reached ahead of schedule
CRDLCardiol Therapeutics Inc.
Cardiol Therapeutics achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule and plans to expand the study to up to 150 patients following a blinded review showing fewer-than-expected pericarditis recurrences. This expansion aims to preserve statistical power for assessing CardiolRx's efficacy in reducing recurrence risk, pushing the anticipated topline results from Q1 2027 to mid-2027. The company expects existing capital to fund completion with a cash runway extending into Q1 2028. Cardiol Therapeutics is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease.